BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Penazzato M, Gnanashanmugam D, Rojo P, Lallemant M, Lewis LL, Rocchi F, Saint Raymond A, Ford N, Hazra R, Giaquinto C, Belew Y, Gibb DM, Abrams EJ; Paediatric Antiretroviral Working Group (PAWG). Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clin Infect Dis 2017;64:1597-603. [PMID: 29190337 DOI: 10.1093/cid/cix194] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Penazzato M, Watkins M, Morin S, Lewis L, Pascual F, Vicari M, Lee J, Hargreaves S, Doherty M, Siberry GK. Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action. The Lancet HIV 2018;5:e259-64. [DOI: 10.1016/s2352-3018(18)30005-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
2 Lee C, Sapasap J, LaRochelle J, Smith RO, Badowski ME. Antiretroviral Therapy in Children and Adolescents: A Look Into Modern Single Tablet Regimens. J Pediatr Pharmacol Ther 2021;26:783-94. [PMID: 34790067 DOI: 10.5863/1551-6776-26.8.783] [Reference Citation Analysis]
3 Maswabi K, Ajibola G, Bennett K, Capparelli EV, Jean-Philippe P, Moyo S, Mohammed T, Batlang O, Sakoi M, Lockman S, Makhema J, Lichterfeld M, Kuritzkes DR, Hughes MD, Shapiro RL. Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clin Infect Dis 2021;72:388-93. [PMID: 31927562 DOI: 10.1093/cid/ciaa028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 Penazzato M, Lewis L, Watkins M, Prabhu V, Pascual F, Auton M, Kreft W, Morin S, Vicari M, Lee J, Jamieson D, Siberry GK. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries. J Int AIDS Soc 2018;21 Suppl 1. [PMID: 29485727 DOI: 10.1002/jia2.25049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Noel GJ, DeBiasi RL, Crandall W, Connor EM. Ensuring continued progress for development of COVID-19 therapeutics in children. Pediatr Res 2021. [PMID: 33603214 DOI: 10.1038/s41390-021-01384-y] [Reference Citation Analysis]
6 Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR, Lallemant M, Gibb DM. Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. J Acquir Immune Defic Syndr 2018;78 Suppl 1:S40-8. [PMID: 29994919 DOI: 10.1097/QAI.0000000000001748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Dirajlal-Fargo S, Koay WLA, Rakhmanina N. Pediatric Antiretroviral Therapy. Handb Exp Pharmacol 2020;261:285-323. [PMID: 31286213 DOI: 10.1007/164_2019_246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Siberry GK, Amzel A, Ramos A, Rivadeneira ED. Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries. J Infect Dis 2017;216:S838-42. [PMID: 29045697 DOI: 10.1093/infdis/jix407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers 2020;6:48. [PMID: 32555389 DOI: 10.1038/s41572-020-0181-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
10 Vreeman RC, Rakhmanina NY, Nyandiko WM, Puthanakit T, Kantor R. Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV. J Int AIDS Soc 2021;24:e25759. [PMID: 34097352 DOI: 10.1002/jia2.25759] [Reference Citation Analysis]
11 Rojo P, Carpenter D, Venter F, Turkova A, Penazzato M. The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV. J Int AIDS Soc 2020;23 Suppl 5:e25576. [PMID: 32869500 DOI: 10.1002/jia2.25576] [Reference Citation Analysis]
12 Saito S, Chung H, Mahy M, Radin AK, Jonnalagadda S, Hakim A, Awor AC, Mwila A, Gonese E, Wadonda-Kabondo N, Rwehumbiza P, Ao T, Kim EJ, Frederix K, Nuwagaba-Biribonwoha H, Musuka G, Mugurungi O, Mushii J, Mnisi Z, Munthali G, Jahn A, Kirungi WL, Sivile S, Abrams EJ. Pediatric HIV Treatment Gaps in 7 East and Southern African Countries: Examination of Modeled, Survey, and Routine Program Data. J Acquir Immune Defic Syndr 2018;78 Suppl 2:S134-41. [PMID: 29994836 DOI: 10.1097/QAI.0000000000001739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, Burger DM; Pediatric Antiretroviral Working Group (PAWG). Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. Ther Drug Monit 2019;41:431-43. [PMID: 31008997 DOI: 10.1097/FTD.0000000000000637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
14 Fairlie L, Waitt C, Lockman S, Moorhouse M, Abrams EJ, Clayden P, Boffito M, Khoo S, Rees H, Cournil A, Venter WF, Serenata C, Chersich M. Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards? J Int AIDS Soc 2019;22:e25372. [PMID: 31529598 DOI: 10.1002/jia2.25372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Abrams EJ, Ananworanich J, Archary M, Ngongondo M, Brouwers P. Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration. J Acquir Immune Defic Syndr 2018;78 Suppl 1:S32-9. [PMID: 29994918 DOI: 10.1097/QAI.0000000000001747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
16 Gaur AH, Cotton MF, Rodriguez CA, McGrath EJ, Helström E, Liberty A, Natukunda E, Kosalaraksa P, Chokephaibulkit K, Maxwell H, Wong P, Porter D, Majeed S, Yue MS, Graham H, Martin H, Brainard DM, Pikora C. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health 2021;5:642-51. [PMID: 34302760 DOI: 10.1016/S2352-4642(21)00165-6] [Reference Citation Analysis]
17 Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J, Struble K, Watts H, Flexner C. Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. Lancet HIV 2019;6:e552-8. [PMID: 31307946 DOI: 10.1016/S2352-3018(19)30147-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
18 Penazzato M, Lule F, Essajee S. Paediatric HIV: the unfinished business. Lancet HIV 2017;4:e425-7. [PMID: 28711527 DOI: 10.1016/S2352-3018(17)30126-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
19 Flynn PM. A broader look at adolescents with perinatal HIV. Nature 2018;556:439-40. [PMID: 29686368 DOI: 10.1038/d41586-018-04476-8] [Reference Citation Analysis]